Pancreatic cancer is one of the deadliest cancers in the world. According to GLOBOCAN and the American Cancer Society, its overall five-year survival rate remains low because most cases are detected when local invasion or metastasis has already occurred. This happens because the initial pancreatic tumor usually grows without clear symptoms. When signs such as weight loss, jaundice, or abdominal pain appear, the disease is often advanced. Therefore, any test capable of detecting it earlier can radically change the prognosis. A key study published in Clinical Cancer Research identified a urinary panel based on three biomarkers—LYVE1, REG1A, and TFF1—capable of differentiating early pancreatic cancer from healthy controls and other pancreatic diseases. The work was led by researchers from the Barts Cancer Institute, Queen Mary University of London, and international collaborators. The authors suggested that this urinary signature could detect some cases up to two years before conventional diagnosis, opening a crucial therapeutic window.

Medical logic is elegant. The tumor alters metabolism and releases specific compounds into the body. Some of these compounds circulate in the blood, are filtered by the kidneys, and appear in the urine.

Modern laboratories look for signals such as:

Tumor proteins: molecules produced in excess by malignant cells.
MicroARN: small regulatory sequences altered in cancer.
Cell-free tumor DNA: genetic fragments shed from the tumor.
Exosomes: nanoparticles released by cancer cells with an identifiable molecular charge.
Metabolites: chemical changes resulting from tumor growth. Subsequently, statistical algorithms or AI models analyze combinations of multiple markers, since a single biomarker is rarely sufficient.

Prostate cancer is one of the most frequently diagnosed tumors in men. For years, the dominant tool was PSA (prostate-specific antigen), a useful but imperfect blood test. The problem with PSA is that it can also be elevated by: benign prostatic hyperplasia, inflammation, infection, and prostate manipulation. This leads to thousands of unnecessary biopsies each year. This is where urine tests are showing advantages. PCA3: one of the first clinical urinary biomarkers. The PCA3 test, approved in several markets, detects prostate cancer-associated RNA in urine following digital prostate massage. It was one of the first real-world examples of urinary cancer diagnosis.

SelectMDx, ExoDx, and other modern systems

New platforms combine urinary genes, exosomes, and clinical algorithms to estimate the risk of aggressive cancer. Studies published in European Urology and other journals show improved ability to select who needs a biopsy.

This not only improves accuracy but also reduces anxiety, costs, and invasive procedures.

What makes this revolution possible is not just the urine sample itself, but the tools that analyze it today. Genetic sequencing allows the detection of minute mutations. Mass spectrometry identifies proteins at ultralow concentrations. Nanostructured biosensors capture biomarkers with unprecedented sensitivity. Artificial intelligence finds patterns invisible to the human eye. In other words: urine hasn't changed; our ability to read it has.

In some cases, potentially, yes, especially if the tumor is still small but metabolically active. However, experts emphasize that these tests do not automatically replace imaging or biopsies. The most likely scenario is a combined model: urine screening test; if there is high risk, MRI or CT scan; histological confirmation when necessary. This stepwise approach would be more efficient and less aggressive for millions of patients.

Although the results are promising, real challenges remain.

Urine composition changes due to hydration, diet, medications, exercise, and benign diseases. Furthermore, a biomarker that is useful in one population may not perform as well in another.

Standardization is also needed, including sampling timing, preservation, processing, diagnostic thresholds, and international multicenter validation; therefore, many tests are still in the clinical or pre-commercial phase.

If a reliable urine test for pancreatic cancer were implemented in at-risk populations—for example, people with a family history, chronic pancreatitis, or unexplained recent diabetes—it could save thousands of lives through early surgery. In prostate cancer, the immediate benefit seems even closer: better selection of patients for biopsy and detection of clinically relevant tumors, thus avoiding overtreatment.

Professor Tatjana Crnogorac-Jurcevic, a leading researcher in pancreatic biomarkers, has pointed out that early detection is one of the greatest opportunities to change the natural history of pancreatic cancer. In urology, European experts emphasize that urinary biomarkers can complement multiparametric MRI and PSA for a smarter strategy. Diagnosing complex diseases using simple, non-invasive samples analyzed with advanced technology. Urine could go from being a basic routine test to becoming a strategic platform for detecting cancer before symptoms appear. We are not yet at a definitive solution, but we are facing one of the most promising lines of next-generation diagnostic oncology.

Scientific references:

1. Radon TP et al. Identification of a three-biomarker panel in urine for early detection of pancreatic adenocarcinoma. Clinical Cancer Research.
2. McKiernan J et al. Urinary exosome gene expression assay for prostate cancer detection. JAMA Oncology.
3. Van Neste L et al. A urinary biomarker-based risk score correlates with prostate cancer. European Urology.
4. American Cancer Society – Pancreatic & Prostate Cancer statistics.
5. Nature Reviews Urology – Emerging urine biomarkers in prostate cancer.